We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI Poised to Transform Outcomes in Cardiovascular Health Care

By HospiMedica International staff writers
Posted on 18 Jul 2022

Employing artificial intelligence (AI) to help improve outcomes for people with cardiovascular disease is the focus of a three-year, USD 15 million collaboration between world-leading experts in machine learning and AI, and outstanding cardiologists and clinicians. More...

The Cardiovascular AI Initiative aims to improve heart failure treatment, as well as predict and prevent heart failure.

Researchers from Cornell University (Ithaca, NY, USA) along with physicians from NewYork-Presbyterian (New York, NY, USA) will use AI and machine learning to examine data from NewYork-Presbyterian in an effort to detect patterns that will help physicians predict who will develop heart failure, inform care decisions and tailor treatments for their patients. The Cardiovascular AI Initiative will develop advanced machine-learning techniques to learn and discover interactions across a broad range of cardiac signals, with the goal of providing improved recognition accuracy of heart failure and extend the state of care beyond current, codified and clinical decision-making rules. It will also use AI techniques to analyze raw data from time series (EKG) and imaging data.

Researchers and clinicians anticipate the data will help answer questions around heart failure prediction, diagnosis, prognosis, risk and treatment, and guide physicians as they make decisions related to heart transplants and left ventricular assist devices (pumps for patients who have reached end-stage heart failure). Future research will tackle the important task of heart failure and disease prediction, to facilitate earlier intervention for those most likely to experience heart failure, and preempt progression and damaging events. Ultimately this would also include informing the specific therapeutic decisions most likely to work for individuals.

“AI is poised to fundamentally transform outcomes in cardiovascular health care by providing doctors with better models for diagnosis and risk prediction in heart disease,” said Kavita Bala, professor of computer science and dean of Cornell Bowers CIS. “This unique collaboration between Cornell’s world-leading experts in machine learning and AI and outstanding cardiologists and clinicians from NewYork-Presbyterian, Weill Cornell Medicine and Columbia will drive this next wave of innovation for long-lasting impact on cardiovascular health care.”

“Artificial intelligence and technology are changing our society and the way we practice medicine,” said Dr. Nir Uriel, director of advanced heart failure and cardiac transplantation at NewYork-Presbyterian, an adjunct professor of medicine in the Greenberg Division of Cardiology at Weill Cornell Medicine and a professor of medicine in the Division of Cardiology at Columbia University Vagelos College of Physicians and Surgeons. “We look forward to building a bridge into the future of medicine, and using advanced technology to provide tools to enhance care for our heart failure patients.”

“Major algorithmic advances are needed to derive precise and reliable clinical insights from complex medical data,” said Deborah Estrin, the Robert V. Tishman ’37 Professor of Computer Science, associate dean for impact at Cornell Tech and a professor of population health science at Weill Cornell Medicine. “We are excited about the opportunity to partner with leading cardiologists to advance the state-of-the-art in caring for heart failure and other challenging cardiovascular conditions.”

Related Links:
Cornell University 
NewYork-Presbyterian 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Knee Arthroscopy Holder
Reison 10-353 XL
New
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.